1. Introduction {#sec0005}
===============

1.1. Historical perspective {#sec0010}
---------------------------

Veterinary clinicians noted in the late 1980s the appearance in U.S. swine herds of a previously unrecognized disease with a clinical presentation of severe reproductive losses in late gestational sows, increases in the number of weak live-born pigs, severe pneumonia in neonatal and nursery pigs, reductions in growth performances and increased mortality ([@bib0170], [@bib0220], [@bib0155]). A similar clinical syndrome was initially described in Germany in 1990 and spread to other countries in Europe over the next few years. Despite several reports describing a number of different agents as the cause of this disease, the causative agent remained unknown leading to the name "mystery swine disease" in the U.S. and either "porcine epidemic abortion and respiratory syndrome" or "blue-ear pig disease" in Europe. The latter name refers to the cyanosis or blue-reddish coloration of ears of pigs with this disease. Once the etiology of this "mystery" disease was established the name swine infertility and respiratory syndrome (SIRS) was suggested by North American investigators while the Europeans preferred porcine reproductive and respiratory syndrome (PRRS). The latter name is now the accepted name for the syndrome.

Researchers at the Central Veterinary Institute (Lelystad, The Netherlands) were the first group to fulfill Koch\'s postulates describing a small, enveloped RNA virus (Lelystad Virus) as the causative agent ([@bib0415], [@bib0375]). A similar virus (VR-2332) was isolated in the U.S. at the same time ([@bib0065], [@bib0020]) and one-year later in Canada ([@bib0085]). Comparison of the sequence of the Lelystad virus, now termed type 1 PRRSV, and North American, or type 2, virus isolates indicated that these viruses shared properties similar to the family *Arteriviridae*, genus *Arterivirus*, that includes lactate-dehydrogenase elevating virus (LDH), equine arteritis virus (EAV) and simian hemorrhagic fever virus ([@bib0020], [@bib0085], [@bib0265], [@bib0015]).

PRRS has now emerged as the most prevalent disease of swine in the world. In the U.S. annual losses to PRRS are estimated at \$560 million ([@bib0305]). The virus and the syndrome continue to evolve with clinical variations of the disease, such as swine mortality and abortion syndrome or atypical PRRS ([@bib0125], [@bib0145], [@bib0045]); the recent pandemics in China of "blue ear disease" or "pig high fever disease" that has resulted in severe losses, affecting millions of pigs with high (∼20%) mortality ([@bib0395], [@bib0010], [@bib0210]); and the highly virulent 1-18-2 strain that emerged in the North Central U.S. in 2007 ([@bib0285]).

Since the original discovery of PRRSV, much has been learned about the disease and the virus. This paper is a brief historical review of these accomplishments. It also serves as an introduction to the set of extensive reviews and articles included in this special issue of Virus Research.

2. The virus {#sec0015}
============

The etiological agent of PRRS is an enveloped, single stranded, positive sense RNA virus with properties similar to the *Arteriviridae* family and placed with the *Coronaviridae* in the order *Nidovirales*, based on similarities in genome organization and expression strategy ([@bib0050]). The 15 kb genome consists of two large open reading frames ORF 1a and 1b that comprise 75% of the viral genome and are translated and processed into 14 non-structural proteins (nsp) that exhibit replicase, protease and polymerase activities required for viral replication ([@bib0265], [@bib0355]). As described in several articles in this issue, reverse genetics and infectious virus clones have become the predominate tools for understanding nsp function ([@bib0130], [@bib0140], [@bib0370], [@bib0445]). In this issue, [@bib0140] explore the functional characterization of the key nsp encoded enzymes for arterivirus RNA synthesis, the nsp9 RNA polymerase and nsp10 helicase, the induction of replication-associated membrane rearrangements (nsp2 and nsp3), and a replicative endoribonuclease (nsp11). [@bib0445] note that at least four viral proteins have been studied as viral antagonists of host defenses: N as a structural protein and three non-structural proteins, nsp1 (nsp1α and nsp1β), nsp2, and nsp11. [@bib0140] identified the nsp3--8 region as possibly containing PRRS virulence factors. An important element in virus replication, the 5′ and 3′ untranslated regions are explored by [@bib0370] using infectious clones. This set of reviews affirms how the technical advancements offered by reverse genetics are already leading to important developments for the understanding of the mechanism of pathogenesis and for the design of novel vaccine approaches.

The seven viral structural proteins are encoded by ORFs 2--7 and expressed from six subgenomic mRNAs that are synthesized as a 3′-coterminal nested set of mRNAs with a common leader sequence at the 5′ end ([@bib0355]). They include three N-glycosylated minor envelope proteins (GP2a, GP3 and GP4), ORF 2b that encodes a non-glycosylated minor protein 2b ([@bib0435]) and the major envelope glycoprotein GP5 that forms a heterodimer with the membrane non-glycosylated protein M ([@bib0235], [@bib0360]). The heterodimer consisting of the GP5 and M proteins is required for infectivity of arteriviruses ([@bib0360]); 2b is also essential for virus infectivity and likely functions as an ion channel to facilitate uncoating of the virus ([@bib0200]). The three main structural proteins N, M and GP5 are required for particle formation and viral infectivity, whereas the minor proteins (GP2a, GP3 and GP4) are essential only for viral infectivity ([@bib0430]). One additional structural protein N, or nucleocapsid protein, is encoded by ORF7 and is highly immunogenic and has served as the main diagnostic protein to detect antibodies to PRRSV ([@bib0090]). The N protein is found in both the cytoplasm (viral particle assembly) and the nucleus where it has an important role in antagonizing cellular gene function. [@bib0115] explored the structural biology of PRRSV and affirmed that based on detailed structural analyses this arterivirus is more closely related to coronaviruses than previously thought.

2.1. Pathogenesis, virulence and attenuation {#sec0020}
--------------------------------------------

The pathogenesis of PRRSV was first reviewed by [@bib0470] and [@bib0330]. Infection begins with the interaction between PRRSV and CD163, which is reviewed in this issue by [@bib0410]. Primary targets for replication are alveolar macrophages of the lung and other cells of the monocyte/macrophage lineage including pulmonary intravascular macrophages, subsets of macrophages in lymph nodes and spleen and intravascular macrophages of the placenta and umbilical cord ([@bib0120], [@bib0195], [@bib0380]). In this issue, [@bib0210] report that the highly pathogenic PRRSV isolate, JXwn06, may possess an expanded tropism to include epithelial cells.

The virus can persist in pigs for long periods of time. The first reported evidence of persistence was transmission of PRRSV from an infected sow to susceptible pigs 99 days post-infection ([@bib0460]). Others have detected (either by virus isolation or swine bioassay) virus in tonsil and lymph nodes up to 132 days after birth in pigs infected in utero ([@bib0025], [@bib0345], [@bib0335]); and from 105 to 157 days post-infection in young pigs ([@bib0005], [@bib0160], [@bib0425]). High levels of viral RNA are present in lymphoid tissues in acutely infected pigs and over time viral loads decrease by 1000-fold or more in tonsil and lymph nodes the primary sites of viral persistence ([@bib0440]). The mechanism of persistence is not completely understood but likely includes the emergence of viral variants which can escape host defenses ([@bib0340]).

Studies using mutations in viral genes or the use of chimeras have established potential roles for certain nsp and structural genes in viral virulence and attenuation. Strains with mutations in the nuclear localization signal of the N protein produce lower levels of viremia, a shorter duration of viremia in pigs, higher levels of neutralizing antibodies and reduced viral persistence in tonsils of pigs compared to pigs given the wild-type virus ([@bib0205], [@bib0315]). Experiments using reverse genetics indicate that virulence is probably multigenic involving nsp3--8 proteins and GP5 ([@bib0185], [@bib0405]). These latter studies indicated that certain PRRSV chimeras produce attenuated clinical signs in either a respiratory ([@bib0405]) or pregnant sow model ([@bib0185]). Finally, the highly virulent strain of PRRSV responsible for the outbreak in China in 2006 contains a unique 30-amino acid deletion in the nsp2 coding region that was presumed to be responsible for the increased virulence of these PRRSV strains. However, a recent study by [@bib0450] indicates that the nsp2 deletion is not associated with virulence of the high fever disease isolates. As reported in this issue, deletions in nsp2 can attenuate replication and virulence ([@bib0130]).

Another area of pathogenesis is the interaction between PRRSV and the fetus. At about 90 days gestation, PRRSV can cross the placenta and infect fetuses. In this issue [@bib0335] describes several novel aspects of fetal infection, including the thymus as the principal sight of virus replication and the induction of antiviral cytokines by the infected fetus, but not the dam.

2.2. Heterogeneity {#sec0025}
------------------

Early studies showed that the Lelystad and VR-2332 strain of PRRSV differ by approximately 40% at the genomic level and are also antigenically distinct ([@bib0265], [@bib0300], [@bib0295]). PRRSV strains are now divided into two genotypes, European genotype (Type 1) and North-American (Type 2), both genotypes circulate globally ([@bib0175], [@bib0465]). Strains within each genotype also vary considerably with sequence differences as high as 20% ([@bib0150], [@bib0250], [@bib0295]). The most variable structural protein is GP5 with 50--55% amino acid homology between North American and European isolates ([@bib0235], [@bib0255], [@bib0295]). In this issue [@bib0350] focus on the evolution of type 1 and 2 PRRSV sequence from a phylogenetic perspective; they assess the potential impact of recombination on the virus epidemiology. [@bib0290] explore hypotheses accounting for rapid expansion and diversification of PRRSV, including mechanisms specific to PRRSV and other arteriviruses, cellular modification processes, and immunological selection. Variability within GP5 may explain the inefficiency of current vaccines to cross-protect against all strains of PRRSV. At present, there are no serological assays that link to variability within a genotype.

2.3. Immunology {#sec0030}
---------------

The quest to achieve a reliable vaccine to prevent clinical disease and re-infection is frustrated by our lack of understanding of virus heterogeneity and what constitutes a protective immune response in the host. PRRSV complicates the ability of the host to respond to infection through several immune evasion capacities (see reviews by [@bib0175], and in this issue, [@bib0110]). PRRSV infection is characterized by a delayed appearance of neutralizing antibodies (often not appearing for 3--4 months post-infection) and a slow development of virus specific interferon responses. PRRSV is able to downregulate the production of inflammatory cytokines such as type 1 interferons (IFN-α, IFN-β), TNF-α, and interleukin-1 (IL-1) ([@bib0400], [@bib0390]). Pigs which clear PRRSV infection have coordinated early expression of IL-1β, IL-8 and IFN-g ([@bib0230]).

Five of the 13 nsps were found to inhibit IFN-β promoter activation ([@bib0040]). The strongest inhibitor of IFN-β was nsp1β, which translocates to the nucleus and inhibits TLR3-mediated signaling pathways ([@bib0040]) as well as TNF-α promoter activity ([@bib0365]). Certain regions in nsp2 that are non-essential for PRRSV replication also downregulate IL-1β and TNF-α ([@bib0060]). The inhibition of this early cytokine production in macrophages and dendritic cells contributes to the weak innate immune response, delayed neutralizing antibody, slow IFN-γ response and a depressed cytotoxic T cell response ([@bib0070]).

Details related to acquired immunity in pigs following PRRSV infection have been reviewed ([@bib0175], [@bib0240], [@bib0465]; and in this issue, [@bib0110], [@bib0445]). Shortly after infection, most antibodies are non-neutralizing and are principally targeted to N and nsp2 proteins. Neutralizing antibodies appear as early as 2--4 weeks after infection but usually do not peak until several weeks to months later ([@bib0215]). The role of neutralizing antibodies has been debated principally because viremia persists in the host in the presence of neutralizing activity. The postulated role of antibody evasion strategies, such as immunodominant "decoy" epitopes that produce non-protective immune responses and "glycan shielding" have been recently reviewed and discussed ([@bib0175]). In this issue [@bib0075] describe the role of GP4 as sight for neutralization as well as the appearance of neutralizing escape mutants.

The T-cell responses to PRRSV are induced 2--8 weeks post-infection ([@bib0030], [@bib0440]) and are detected against all structural proteins encoded by ORFs 2--7 ([@bib0035]). Overall, the abundance of T-cells in either acute or persistent infection is highly variable and does not correlate with the level of virus replication in lymphoid tissues ([@bib0440]). Additional studies have shown that the number of PRRSV specific IFN-γ producing T-cells following infection are low in PRRSV infected pigs compared to pigs vaccinated with a pseudorabies vaccine ([@bib0245]). In summary, T-cell responses to PRRSV are generally classified as weak, transient and highly variable. One lingering question is whether there are conserved T-cell epitopes that may provide cross-protection against PRRSV strains ([@bib0175]).

In this issue [@bib0225] focus on genomic approaches to identify biomarkers that define genes and pathways that are correlated with swine resistance to PRRSV infection. Besides helping to identify PRRS resistant pigs, these studies may reveal alternate PRRSV control mechanisms that can be exploited for novel drugs, biotherapeutics and vaccine designs.

2.4. Vaccines {#sec0035}
-------------

The first modified-live vaccine for PRRSV, RespPRRS^®^ (later RespPRRS^®^ Repro and now Ingelvac^®^ PRRS MLV), was released in November 1994 by Boerhringer Ingelheim Animal Health. This modified-live vaccine was prepared by sequential passage of a PRRSV in a monkey kidney cell line CL-2621. Since the release of this vaccine a number of other modified-live and killed-virus vaccines have been developed in the U.S. and Europe ([@bib0260]).

In 2007, a "Colloquium on Prospects for Development of an Effective PRRS Virus Vaccine" was convened with academic, biologic industry representatives and swine practitioners at the University of Illinois ([@bib0325]). Three general questions were posed to the colloquium participants: (1) what is the efficacy of current PRRS vaccines; (2) what knowledge gaps need to be filled to improve the efficiency of current vaccines and to develop more efficacious PRRS vaccines; and (3) what is the probability that a successful PRRS vaccine can be developed. As to the efficacy it is clear that modified-live PRRS vaccines offer protection against reinfection with homologous and in some cases heterologous viruses. Killed-virus vaccines were viewed as ineffective or of limited efficacy at best against homologous protection. The key question is how to deal with the heterogeneity of PRRSV field isolates and provide cross-protection among heterologous strains of virus. The concept of "heterologous" in terms of PRRSV vaccines remains undefined. Properties of an improved vaccine should include rapid induction of immunity (innate immunity), no adverse outcomes to swine health and the ability to differentiate vaccinated from infected animals (DIVA vaccine) ([@bib0105], [@bib0135]). Considerations for the development of vaccines, adjuvants ([@bib0055]), and novel designs are reviewed and discussed in this issue by [@bib0385], [@bib0165] and [@bib0080]. [Table 1](#tbl0005){ref-type="table"} highlights continuing issues that must be addressed for effective PRRS vaccines.Table 1Gaps in our understanding of PRRS and PRRSV vaccines.What are the determinants of protective immunity?What is the role of innate and acquired immunity in PRRS?Which viral proteins bear B- and T-cell epitopes capable of inducing a protective response?What are the main methods for immune evasion of this virus?What is the definition of "heterologous protection" and what viral proteins are involved in the heterogeneity?What are the conserved regions of the virus genome that may function to induce a protective response?Can conserved viral protein epitopes be exploited to increase the breath of immune protection?

2.5. Epidemiology and methods to control PRRSV {#sec0040}
----------------------------------------------

Several studies have established the role of infected pigs and semen, and the role of equipment and objects that move between swine farms, as important for herd to herd transmission (see [@bib0465]). Others have proposed area spread from neighboring farms as the major form of herd to herd transmission ([@bib0280]). Proximity to infected herds is recognized as a risk factor with the risk increasing with the density of PRRSV-positive neighboring herds, but decreasing as the distance from positive herds increases ([@bib0455]). Could PRRSV be transmitted between herds over distances via aerosols? Airborne transmission could explain area spread in the absence of other sources such as movement of infected pigs, semen, fomites, and breakdowns in biosecurity protocols ([@bib0095], [@bib0320]).

The PRRSV replicates in alveolar macrophages in the lung and in the tonsil of infected pigs. Thus, the potential for aerosol spread through respiratory and oropharyngeal excretions within swine confinement units is a distinct possibility. In this issue, [@bib0180] describe the use of oral fluids a convenient means to track infections in the field. Early laboratory experiments to prove aerosol transmission were disappointing and the conclusion was that aerosol transmission was not common and difficult to achieve over short distances of 1.0--2.5 m ([@bib0190], [@bib0310], [@bib0420]). In contrast, observations in the field were that extensive efforts to eliminate and eradicate PRRSV from swine herds, while initially successful, always seemed to result in re-infection of these herds and the only explanation appeared to be area spread through aerosols. In this issue, [@bib0100] describe the use of air filtration systems in the field as an effective means to reduce transmission.

3. Conclusions {#sec0045}
==============

Since the discovery of a virus as the etiologic agent of PRRS in the early 1990s, PRRSV continues to be a major economic issue for the swine industry worldwide. Through the efforts of many scientists throughout the world a better understanding of the virology, pathogenesis, immunology, genetic resistance, epidemiology and vaccinology has been gained. Within three years after the discovery of the PRRSV, a modified-live vaccine became available and was quickly used throughout swine producing areas in the world. The question of what drives the evolution of this virus in the field and how to provide cross-protection versus heterologous field strains remains an important and unresolved question.

Despite our lack of understanding of the innate and acquired immune response to PRRSV, it should be remembered that the host eventually eliminates the virus. Experimental evidence indicates that PRRSV is eventually eliminated from the host and persistent infection rarely last more than 200 days ([@bib0285]). Veterinarians have used this information to develop the concept of "herd closure" as a means to eliminate PRRSV from herds. In herd closure all animals are exposed to PRRSV by vaccination or inoculation with virulent virus and then the herd is closed to all animal entry for 200 days. When naïve gilts are introduced into these herds they remain negative. If there are re-breaks, it is almost always with a virus of a different genotype thus indicating a new outbreak ([@bib0285]). This protocol is being used in "regional elimination programs" throughout the U.S. in an effort to eliminate PRRSV from less dense swine areas. The combination of vaccines, herd closure, biosecurity protocols and filtration units on swine housing to prevent area spread may well become the protocol for elimination of this virus in regional areas, as reviewed in this issue by [@bib0275].

One of the important lessons learned with PRRS is that understanding this virus and the associated syndrome requires an integrated effort of researchers in various disciplines in collaboration with swine veterinarians. Such interactions would not have been possible without the support of funding programs such as the USDA PRRS Coordinated Agricultural Project (CAP) grants (<http://www.prrs.org/>), the National Pork Board PRRSV Initiative (<http://www.pork.org/Research/>), and the yearly updates presented at the International PRRSV Symposium (<http://www.prrssymposium.org/>).

This work is supported by the PRRS CAP, USDA NIFA Award 2008-55620-19132.

[^1]: Tel.: +1 330 263 3703; fax: +1 330 263 3688.
